Nonalcoholic steatohepatitis (NASH) drugs market

被引：54
|
作者：
Cassidy, Sorcha [1 ]
Syed, Basharut A. [1 ]
机构：
[1] PSL Grp, FirstWord Pharma, 75 Davies St, London W1K 5JN, England
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 11期
关键词：
D O I：
10.1038/nrd.2016.188
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [31] Insulin Resistance, Reason or Consequence Nonalcoholic Steatohepatitis (NASH)
    Akbari, Hamed
    Vakili, Sina
    Aria, Hamid
    Taghadosi, Roholah
    Alavi, Seyed Ali
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2015, 6 (03): : 1861 - 1865
  • [32] Predicting nonalcoholic steatohepatitis (NASH) using mechanistic biomarkers
    Tan, Eunice
    Jumat, Nur Halisa
    Soon, Gwyneth Shook Ting
    Lee, Jonathan Wei Jie
    Dan, Yock Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 425 - 425
  • [33] Cells to Prevent the Development and Progression of Nonalcoholic Steatohepatitis (NASH)
    Sun, Guangyong
    Zhang, Chunpan
    Jin, Hua
    Shi, Wen
    Wang, Tianqi
    Zhang, Dong
    HEPATOLOGY, 2018, 68 : 64A - 64A
  • [34] Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
    Van Meeteren, Menso J. Westerouen
    Drenth, Joost P. H.
    Tjwa, Eric T. T. L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 117 - 123
  • [35] Innate immunity involved in the pathogenesfs of nonalcoholic steatohepatitis (NASH)
    不详
    LIVER TRANSPLANTATION, 2006, 12 (10) : 1553 - 1554
  • [36] The Central Zone "Portalization" Phenomenon in Nonalcoholic Steatohepatitis (NASH)
    Oliver-Krasinski, J. M.
    Peruyero, L. C.
    Moreira, R. K.
    LABORATORY INVESTIGATION, 2012, 92 : 420A - 421A
  • [37] Proteomic study of steatosis and nonalcoholic steatohepatitis (NASH) by DIGE
    Elortza, F.
    Fernandez, E.
    Gomara, C.
    Alkorta, N.
    Rodriguez, E.
    Duce, A. M.
    Caballeria, J.
    Martinez Chantar, M. L.
    Mato, J. Maria
    MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (10) : S54 - S54
  • [38] Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity?
    Brunt, EM
    LIVER, 1999, 19 (04): : 263 - 264
  • [39] A new method to induce nonalcoholic steatohepatitis (NASH) in mice
    Feryal Savari
    Seyyed Ali Mard
    Mohammad Badavi
    Anahita Rezaie
    Mohammad Kazem Gharib-Naseri
    BMC Gastroenterology, 19
  • [40] DISCOVERY OF AN EARLY DIAGNOSTIC BIOMARKER OF NONALCOHOLIC STEATOHEPATITIS ( NASH)
    Tanya Nguyen
    Nieser, Carla
    HEPATOLOGY, 2023, 78 : S794 - S795
12345